TG Therapeutics, Inc. (TGTX) announced that 82% of patients in its Phase 1 study of subcutaneous BRIUMVI for myasthenia gravis achieved a clinically meaningful improvement in daily living scores, with a mean gain of more than four points.
The trial enrolled 11 adults with AChR-antibody-positive myasthenia gravis, showing consistent reductions across disease measures over 24 weeks. Median time to improvement was 30 days, and the therapy was generally well tolerated, with safety in line with the established IV formulation.
Building on these results TG has initiated a randomized Phase 2 study designed as a potential registration-directed trial. The approach combines rapid symptom control from FcRn inhibition with longer-term disease modification through B-cell depletion, aiming to reduce the burden of chronic therapy.
CEO Michael S. Weiss said the findings mark an important milestone in expanding BRIUMVI's potential beyond multiple sclerosis, underscoring the company's strategy to establish a differentiated treatment paradigm in multiple sclerosis, underscoring the company's strategy to establish a differentiated treatment paradigm in myasthenia gravis.
TGTX has traded between $25.28 and $44.65 over the past year. The stock is currently trading at $42.14, up 2.91%.
For comments and feedback contact: editorial@rttnews.com
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.